Wow, you sold out completely Ma? I was wondering why I hadn't seen any of your excellent research.
Whilst its old news now, and radiopharma doesn't appear to have been much in the news lately, it's relevant to highlight the comments in the Bell Potter latest Valuation:
"From a trade buyers perspective, data from the expansion cohort should support a bid for the company at a value reflective of other M&A in the space. We expect the expansion cohort data in late CY25 or early CY26. Patients will be dosed concurrently, i.e. all patients likely to receive first dose in the June quarter."
The last Bid for a Radiopharmaceuticals company was US$2.4 billion, and seems to me Clarity continues to advance slowly, it's better safety and efficacy, on small cohort sizes. But it's development is building. At a current mkt cap of ~US$0.5 billion seems to me Clarity could easily get a Bid in excess of 5 x current price!
As Bell Potter points out: "Our valuation on speculative stocks is limited to 100% upside from market price, hence valuation reduced to $5.20 (prev $10.00). We believe the clinical data continues to be outstanding for both safety and efficacy, hence in our view there is a severe dislocation between intrinsic value and the current share price. We maintain our Buy (Speculative) ratin. ie Clarity's share price could easily be much higher in a flash! I continue to Buy!
CU6 Price at posting:
$2.83 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)